MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • 2023 International Congress

    Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube

    M. Hebert, A. Mar, R. Moore, A. Bristow, S. Siegert (San Diego, USA)

    Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…
  • 2022 International Congress

    Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.

    D. López Domínguez, B. Solano Vila, A. Cots Foraster (Girona, Spain)

    Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…
  • 2022 International Congress

    The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit

    K. Anderson, M. Konings, S. Finkbeiner, A. Cutler (Washington, USA)

    Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…
  • 2022 International Congress

    Levosulpiride and Movement Disorders–A Growing Concern

    D. Radhakrishnan, S. Gomathy, R. Rajan, A. Srivastava, A. Das, A. Agarwal, A. Pandit, V. Goyal (New Delhi, India)

    Objective: To describe a series of patients with levosulpiride (LVS) induced movement disorders (LIM) evaluated at a single movement disorder center, the All India Institute…
  • 2022 International Congress

    A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS

    R. Anand, S. Pandey, HS. Malhotra, RK. Garg, N. Kumar, R. Uniyal, I. Rizvi (Lucknow, India)

    Objective: We aimed to characterize the spectrum of DIMDs, and the culprit agents commonly encountered in the movement disorder clinic. We also set out to…
  • 2022 International Congress

    Novel Antipsychotics and Risk of Drug-Induced Movement Disorders and Tardive Syndromes

    G. Kannarkat, S. Caroff, J. Morley (Philadelphia, USA)

    Objective: To review evidence on the risk of drug-induced movement disorders (DIMDs) with newer antipsychotic (AP) drugs. Background: DIMDs, both acute/subacute “extrapyramidal symptoms” and chronic…
  • 2022 International Congress

    Trending the educational needs of US physicians related to managing patients with tardive dyskinesia

    W. Cerenzia, S. Wiley, B. Coleman, S. Stacy, E. Jen, K. Farahmand, S. Siegert, C. Shah (Birmingham, USA)

    Objective: This study sought to understand evolving continuing medical education (CME) needs of US physicians managing patients with tardive dyskinesia (TD) by assessing the knowledge, practice, and barriers at three timepoints…
  • MDS Virtual Congress 2021

    Reanalysis of a Patient-Reported Outcome (Tardive Dyskinesia Impact Scale) Shows Positive Results

    D. Stull, M. Bron, S. Bean, B. Williams, R. Farber, E. Franey, C. Yonan, R. Dhanda (New York, USA)

    Objective: To reanalyze the Tardive Dyskinesia Impact Scale (TDIS) and assess its potential utility in future TD studies. Background: TD is a persistent and potentially…
  • MDS Virtual Congress 2021

    Impacts of Tardive Dyskinesia (TD) Symptoms on Patients: Analysis of a TD-Specific Patient-Reported Outcome

    D. Stull, M. Bron, S. Bean, B. Williams, R. Farber, E. Franey, C. Yonan, R. Dhanda (New York, USA)

    Objective: To understand the impact of tardive dyskinesia (TD) symptoms on patients, confirm the appropriateness of the Tardive Dyskinesia Impact Scale (TDIS) as a patient-reported…
  • MDS Virtual Congress 2021

    Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia

    C. Correll, T. Carmack, C. Shah, L. Lundt (Glen Oaks, USA)

    Objective: To characterize different patterns of improvement with valbenazine (VBZ) in patients with tardive dyskinesia (TD) using Abnormal Involuntary Movement Scale (AIMS) data from KINECT…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley